Asher, N.; Ben-Betzalel, G.; Lev-Ari, S.; Shapira-Frommer, R.; Steinberg-Silman, Y.; Gochman, N.; Schachter, J.; Meirson, T.; Markel, G.
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. Cancers 2020, 12, 2329.
https://doi.org/10.3390/cancers12082329
AMA Style
Asher N, Ben-Betzalel G, Lev-Ari S, Shapira-Frommer R, Steinberg-Silman Y, Gochman N, Schachter J, Meirson T, Markel G.
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. Cancers. 2020; 12(8):2329.
https://doi.org/10.3390/cancers12082329
Chicago/Turabian Style
Asher, Nethanel, Guy Ben-Betzalel, Shaked Lev-Ari, Ronnie Shapira-Frommer, Yael Steinberg-Silman, Neta Gochman, Jacob Schachter, Tomer Meirson, and Gal Markel.
2020. "Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma" Cancers 12, no. 8: 2329.
https://doi.org/10.3390/cancers12082329
APA Style
Asher, N., Ben-Betzalel, G., Lev-Ari, S., Shapira-Frommer, R., Steinberg-Silman, Y., Gochman, N., Schachter, J., Meirson, T., & Markel, G.
(2020). Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. Cancers, 12(8), 2329.
https://doi.org/10.3390/cancers12082329